As one of the most reliable predictors of treatment outcomes for multiple forms of cancer, Measurement of Residual Disease (MRD) testing presents many new opportunities for improvement in clinical trials.
complimentary white paper
, discover best practices revealed by our top oncology experts in MRD testing that you should be using now in your drug development program. Our experts will also discuss the advantages and disadvantages of two leading approaches in MRD testing – Genomics and Flow Cytometry – and how to choose the most optimal one for your particular study.
today to discover how we can use our deep scientific expertise and global laboratory footprint to improve patient care in your MRD testing programs.
About the authors:
, Director, Scientific Advisor, Flow Cytometry
, Ph.D., Senior Director and Global Head, Translational Genomics
, M.D., M.Sc., FCAP, Director of Hematopathology